Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis

Archives of Cardiovascular Diseases
Mathieu KerneisGilles Montalescot

Abstract

A novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing an international outbreak of respiratory illness described as coronavirus disease 2019 (COVID-19). SARS-CoV-2 infects human cells by binding to angiotensin-converting enzyme 2. Small studies suggest that renin-angiotensin system (RAS) blockers may upregulate the expression of angiotensin-converting enzyme 2, affecting susceptibility to SARS-CoV-2. This may be of great importance considering the large number of patients worldwide who are treated with RAS blockers, and the well-proven clinical benefit of these treatments in several cardiovascular conditions. In contrast, RAS blockers have also been associated with better outcomes in pneumonia models, and may be beneficial in COVID-19. This review sought to analyse the evidence regarding RAS blockers in the context of COVID-19 and to perform a pooled analysis of the published observational studies to guide clinical decision making. A total of 21 studies were included, comprising 11,539 patients, of whom 3417 (29.6%) were treated with RAS blockers. All-cause mortality occurred in 587/3417 (17.1%) patients with RAS blocker treatment and in 982/8122 (12.1%) patients without RAS blocker ...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Feb 15, 2001·Biochemistry. Biokhimii︠a︡·L A Belova
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
May 29, 2004·Trends in Pharmacological Sciences·Anthony J TurnerNigel M Hooper
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Jul 8, 2005·Nature·Yumiko ImaiJosef M Penninger
Oct 14, 2005·Kidney International·Carlos M FerrarioMark C Chappell
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Mar 30, 2007·The American Journal of Pathology·Jiang Gu, Christine Korteweg
May 21, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shiori HagaYukihito Ishizaka
Nov 13, 2008·The New England Journal of Medicine·Barry M MassieUNKNOWN I-PRESERVE Investigators

❮ Previous
Next ❯

Citations

Jun 9, 2021·Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association·Nicolas GirerdJean-Jacques Mourad

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT04329195
NCT04364893
NCT04351581
NCT04353596
NCT04330300
NCT04338009
NCT04311177
NCT04312009
NCT04340557
NCT04335786

Software Mentioned

Review Manager ( RevMan )

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.